IRD (Opus Genetics) Research & Development: $33.44 Mil (TTM As of Mar. 2026)


IRD Opus Genetics Inc IRD
24 GF Score
Price $3.63
GF Value $0.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Opus Genetics Research & Development?

Opus Genetics IRD -2.16% 24 Research & Development is $33.44 Mil as of Mar. 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Opus Genetics's Research & Development for the three months ended in Mar. 2026 was $10.58 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $33.44 Mil.

Opus Genetics  (NAS:IRD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Opus Genetics Research & Development Related Terms

Opus Genetics Research & Development Historical Data

* Premium members only.

The historical data trend for Opus Genetics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opus Genetics Research & Development Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 15.17 14.36 17.65 26.85 30.81

Opus Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.95 6.02 6.41 10.43 10.58
IRD
24GF Score
Opus Genetics Inc IRD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Opus Genetics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $33.44 Mil mean?
Opus Genetics (IRD) has a Research & Development of $33.44 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Opus Genetics and its competitors.
Is Opus Genetics' Research & Development too high?
Opus Genetics' current Research & Development is $33.44 Mil. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Opus Genetics' Research & Development compare to IFRX and RGNX?
Opus Genetics' Research & Development of $33.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Opus Genetics and its competitors. Opus Genetics's current Research & Development is $33.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Opus Genetics stock overvalued right now?
Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $3.63 — trading 879.7% above its estimated fair value. The current Research & Development is $33.44 Mil. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Opus Genetics (IRD), the current Research & Development is $33.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $3.63 is trading 879.7% above its estimated GF Value™ of $0.37. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

  • Research & Development: $33.44 Mil
  • GF Value™: $0.37 vs. price of $3.63 (879.7% above fair value)
  • GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Opus Genetics Business Description

Other Exchanges R3X1:Germany
Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score

Get the complete analysis for IRD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.63
Price
$0.37
GF Value